Abstract:
Objective A method that is based on microfluidic cell chip technology was developed for the first time to analyze CD14+ monocyte myeloperoxidase (MPO) expression in myelomonocytic leukemia (M4) patients. CD14+ monocyte MPO expression in M4 patients was preliminarily discussed.
Methods a. The chip was prepared by using polydimethylsiloxane as the host material and by secondary foam molding. b. A total of 48 clinically diagnosed M4 patients and 52 patients with normal myelogram were included as the test and control groups, respectively. c. A method based on the microfluidic cell chip approach was established to detect CD14+ monocytes and to determine the positive rate and degree of MPO expression in the cells. d. The microfluidic cell chip technique was used to compare CD14 + monocyte MPO expression in M4 patients with that in the control.
Results a. The designed microfluidic single cell analysis chip allowed the entry of granulocytes into the corresponding microfluidic channels. Thus, blood cells were separated. Numerous ghost corpuscles surrounded the separated white blood cells (WBCs). WBC morphology did not show obvious changes. b. The positive rate of MPO expression and the activity of CD14 + monocytes in the bone marrow of M4 patients were significantly higher than those in the bone marrow of the control (P < 0.05).
Conclusion A method based on microfluidic single cell technology was developed for the first time to analyze the MPO expression in CD14+ monocytes. CD14+ monocyte MPO activity in M4 patients was significantly higher than in the control. CD14+ monocyte MPO activity can be used as an auxiliary examination marker for clinical diagnosis.
下载: